Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 13/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL731986 | 1.00 | CASP1 (0.39) | CASP1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1983553 | 0.87 | PDF (0.34) | CASP1ALDH1A1 | |
| SCHEMBL731309 | 0.87 | PDF (0.34) | CASP1ALDH1A1 | |
| SCHEMBL14943742 | 0.87 | SMN1; SMN2 (0.38) | CASP1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL12401070 | 0.85 | SMN1; SMN2 (0.37) | CASP1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL15338738 | 0.85 | SMN1; SMN2 (0.37) | CASP1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL15896316 | 0.85 | SMN1; SMN2 (0.32) | CASP1SMN1; SMN2 | |
| SCHEMBL731552 | 0.84 | ALDH1A1 (0.35) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1988212 | 0.84 | ALDH1A1 (0.35) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL12466907 | 0.84 | SMN1; SMN2 (0.39) | CASP1SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101754974-B | As the macrocylc compound of antiviral agent | MSD ITALIA S.R.L. (IT) | 2016-02-03 | — | — | CN | disclosed |
| EP-2331552-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2331552-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010036551-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20100080770-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080770-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | CASP1 3218/4885SMN1; SMN2 4675/4885ALDH1A1 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.